ADC Therapeutics 
Welcome,         Profile    Billing    Logout  
 4 Products   4 Diseases  4 Products   1 Trial   232 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
2020-004181-20: Camidanlumab Tesirine in elderly patients with Hodgkin lymphoma who failed to achieve an adequate response with first-line treatment or relapsed thereafter. Camidamlumab tesirine nei pazienti anziani con Linfoma di Hodgkin che non hanno risposto adeguatamente a un primo trattamento o sono ricaduti dopo averlo terminato

Not yet recruiting
2
46
Europe
Camidanlumab tesirine, [ADCT-301], Lyophilisate for solution for injection
ISTITUTO EUROPEO DI ONCOLOGIA, ADC Therapeutics SA
Relapsed or refractory Hodgkin's lymphoma after first-line chemotherapy or at high risk of failure, as defined by persistence of PET-positivity after the first two courses of first-line chemotherapy in elderly patients = 60 years of age. Linfoma di Hodgkin recidivato o refrattario dopo la prima linea di chemioterapia o ad alto rischio di fallimento, come definito dalla persistenza di PET-positività dopo i primi due cicli di chemioterapia di prima linea nei pazienti anziani di età = 60 anni., Elderly patients who have failed a first line of therapy or who are at high risk of relapse. Pazienti Anziani che hanno fallito una prima linea di terapia o che sono ad altro rischio di ricaduta., Diseases [C] - Cancer [C04]
 
 
NCT04639024: ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Terminated
2
3
US
ADCT-301, Camidanlumab tesirine
Gwynn Long, M.D., ADC Therapeutics S.A.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
11/22
11/22
NCT04052997 / 2018-002556-32: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
2
117
Europe, Canada, US, RoW
Camidanlumab Tesirine, ADCT-301
ADC Therapeutics S.A.
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
01/23
01/23
ADCT-701 / ADC Therapeutics
NCT06041516: Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Recruiting
1
70
US
ADCT-701
National Cancer Institute (NCI)
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
10/27
10/29
ADCT-502 / ADC Therapeutics
No trials found
ADCT-212 / ADC Therapeutics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
2020-004181-20: Camidanlumab Tesirine in elderly patients with Hodgkin lymphoma who failed to achieve an adequate response with first-line treatment or relapsed thereafter. Camidamlumab tesirine nei pazienti anziani con Linfoma di Hodgkin che non hanno risposto adeguatamente a un primo trattamento o sono ricaduti dopo averlo terminato

Not yet recruiting
2
46
Europe
Camidanlumab tesirine, [ADCT-301], Lyophilisate for solution for injection
ISTITUTO EUROPEO DI ONCOLOGIA, ADC Therapeutics SA
Relapsed or refractory Hodgkin's lymphoma after first-line chemotherapy or at high risk of failure, as defined by persistence of PET-positivity after the first two courses of first-line chemotherapy in elderly patients = 60 years of age. Linfoma di Hodgkin recidivato o refrattario dopo la prima linea di chemioterapia o ad alto rischio di fallimento, come definito dalla persistenza di PET-positività dopo i primi due cicli di chemioterapia di prima linea nei pazienti anziani di età = 60 anni., Elderly patients who have failed a first line of therapy or who are at high risk of relapse. Pazienti Anziani che hanno fallito una prima linea di terapia o che sono ad altro rischio di ricaduta., Diseases [C] - Cancer [C04]
 
 
NCT04639024: ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Terminated
2
3
US
ADCT-301, Camidanlumab tesirine
Gwynn Long, M.D., ADC Therapeutics S.A.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MDS/MPN)
11/22
11/22
NCT04052997 / 2018-002556-32: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
2
117
Europe, Canada, US, RoW
Camidanlumab Tesirine, ADCT-301
ADC Therapeutics S.A.
Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
01/23
01/23
ADCT-701 / ADC Therapeutics
NCT06041516: Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Recruiting
1
70
US
ADCT-701
National Cancer Institute (NCI)
Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical, Carcinoma, Adrenal Cortical
10/27
10/29
ADCT-502 / ADC Therapeutics
No trials found
ADCT-212 / ADC Therapeutics
No trials found

Download Options